سعر البالوران 120 مجم 2026

Elbaluran 120 mg film-coated tablets (lurasidone), 30 tablets, Apex Pharma, Egypt.

• Schizophrenia in adults and adolescents (13–17 years).Population: Adults; adolescents 13–17DailyMed / FDA
• Depressive episode associated with bipolar I disorder (bipolar depression) as monotherapy (adults and pediatrics 10–17) or adjunctive with lithium/valproate (adults).Population: Adults; pediatrics 10–17 (monotherapy)DailyMed / FDA

• Common (≥5% and ≥2× placebo): somnolence, akathisia, extrapyramidal symptoms, nausea (schizophrenia adults); similar EPS/akathisia/somnolence patterns in bipolar depression; pediatric profiles include nausea, weight increase, insomnia in some studies (see Latuda label tables).International label, same formulation · DailyMed / FDA

• Known hypersensitivity to lurasidone or formulation components. Concomitant strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, ritonavir, voriconazole). Concomitant strong CYP3A4 inducers (e.g. rifampin, St. John's wort, carbamazepine, phenytoin).International label, same formulation · DailyMed / FDA

• BOXED WARNING: Increased mortality in elderly with dementia-related psychosis — not approved for that use. Antidepressants increase suicidal thoughts/behaviors in pediatric and young adult patients — monitor. Also: cerebrovascular events in elderly dementia, NMS, tardive dyskinesia, metabolic changes (glucose, lipids, weight), hyperprolactinemia, leukopenia/neutropenia, orthostatic hypotension/syncope, falls, seizures, cognitive/motor impairment, body temperature dysregulation, mania/hypomania activation, dysphagia, sensitivity in Parkinson/DLB.International label, same formulation · DailyMed / FDA

• Strong CYP3A4 inhibitorsMajorContraindicated; markedly increase lurasidone exposure.DailyMed / FDA
• Strong CYP3A4 inducersMajorContraindicated; decrease lurasidone exposure.DailyMed / FDA
• Moderate CYP3A4 inhibitors (e.g. diltiazem)ModerateReduce Latuda dose to half of original; start 20 mg/day; max 80 mg/day. Avoid grapefruit.DailyMed / FDA

• Neonates exposed to antipsychotics in third trimester at risk for extrapyramidal and/or withdrawal symptoms. Limited human data; animal studies no teratogenicity at studied multiples of MRHD. Pregnancy registry available (US).International label, same formulation · DailyMed / FDA
• Lactation studies not conducted for presence in human milk; present in rat milk. Weigh benefits of breastfeeding against maternal need and potential infant effects.International label, same formulation · DailyMed / FDA

• Lurasidone hydrochloride: Efficacy thought to be mediated via central dopamine type 2 (D2) and serotonin type 2 (5-HT2A) receptor antagonism (US Latuda label).